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GGGGCC repeat expansions in the C9orf72 gene have been identified as a major
contributing factor in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD). Given the overlapping of clinical phenotypes and pathological
characteristics between these two diseases and Alzheimer’s disease (AD), Parkinson’s
disease (PD), and essential tremor (ET), we speculated regarding whether C9orf72 repeat
expansions also play a major role in these three diseases. Using the repeat-primed
polymerase chain reaction method, we screened for C9orf72 in three groups of patients
with PD (n = 911), AD (n = 279), and ET (n = 152) in the Chinese Han population. There
were no pathogenic repeats (>30 repeats) detected in either the patients or controls
(n = 314), which indicated that the pathogenic expansions of C9orf72 might be rare in
these three diseases. However, the analysis of the association between the number of
repeats (p = 0.001), short/intermediate genotype (short: <7 repeats; intermediate: ≥7
repeats) (odds ratio 1.37 [1.05, 1.79]), intermediate/intermediate genotype (Odds ratio
2.03 [1.17, 3.54]), and PD risks indicated that intermediate repeat alleles could act as
contributors to PD. To the best of our knowledge, this study is the first to reveal the
correlation between C9orf72 and Chinese PD, AD, or ET patients. Additionally, the results
of this study suggest the novel idea that the intermediate repeat allele in C9orf72 is most
likely a risk factor for PD.
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INTRODUCTION
A hexanucleotide (GGGGCC) repeat expansion in the first intron
of the C9orf72 gene was recently identified as a major con-
tributing factor to the chromosome 9p21-linked diseases amy-
otrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) (Dejesus-Hernandez et al., 2011). As previously reported,
theC9orf72mutation accounts for 23.5–47% of familial ALS/FTD
and 4.1–21.0% of sporadic ALS in white populations (Dejesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al.,
2012). The pathogenic mechanism of repeat expansions primarily
includes interference with the normal expression of the encoded
protein or the loss of protein function through the generation of
abnormal toxic RNA foci that disrupt normal cellular pathways
(Renton et al., 2011; Sha and Boxer, 2012).
There is no doubt that the overlapping presentations of clin-
ical phenotypes, pathological characteristics, and gene muta-
tions exist among Parkinson disease (PD), Alzheimer’s disease
(AD), and ALS/FTD (Hudson, 1981; Piguet et al., 2011; Arighi
et al., 2012; Floris et al., 2012; O’Dowd et al., 2012). First,
in the examination of clinical phenotypes, relatives of patients
with ALS have an increased risk for developing PD and AD,
additionally, some ALS/FTD patients have developed the associ-
ated features of Parkinsonism and movement disorders (Hsiung
et al., 2012; Takada et al., 2012; Kohli et al., 2013). Second,
the presence of TAR DNA-binding protein-43(+) intranuclear
inclusions, which are the pathological feature of chromosome
9p21-linked ALS/FTD, have been detected in PD and AD patients
(Nakashima-Yasuda et al., 2007; Boeve et al., 2012). Finally,
mutations in the microtubule-associated protein tau (MAPT)
gene could cause a spectrum of phenotypes which include ALS,
Parkinsonism, and cognitive impairment (O’Dowd et al., 2012).
Given the considerations above, one question has yet to be
addressed. Could the C9orf72 repeat expansions account for
other neurodegenerative disorders, such as AD, PD, and essential
tremor (ET)?
In C9orf72, Repeat expansions exceeding 30 units have been
suggested to be pathological in ALS/FTD patients (Dejesus-
Hernandez et al., 2011). Interestingly, pathogenic expansions have
also been observed in patients with PD, AD, progressive supranu-
clear palsy, corticobasal degeneration, and Lewy body dementia
(Xi et al., 2012; Cacace et al., 2013; Lesage et al., 2013), which fur-
ther indicates that the phenotypes that are associated with repeat
expansions could include the spectrum of cognitive impairment
and movement disorder syndromes. In addition, a previous study
has demonstrated that the role of intermediate repeats (7–24
repeat units) is strongly associated with these diseases and the
expression of C9orf72. The significantly decreased transcriptional
activity of C9orf72 with an increasing number of normal repeats
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indicates that intermediate repeats may act as predisposing alleles
and favors the loss-of-function disease mechanism (Van Der Zee
et al., 2013).
In this study, we first assess the prevalence of C9orf72 repeat
expansions in a large cohort of Chinese Han patients with AD,
PD, or ET to determine whether repeat expansions play a role in
these three common disorders. Furthermore, we explore whether
repeat expansions of intermediate repeats might be a risk factor
for AD, PD, or ET, and/or could affect the age at onset in patients
with these three diseases.
MATERIALS AND METHODS
STUDY SAMPLES
Three independent series of patients participated in this study: the
first cohort of 911 sporadic PD patients that met the UK brain
bank diagnosis criteria (Hughes et al., 1992); the second cohort
of 279 sporadic AD patients that met the NINCDS-ADRDA cri-
teria for probable or definite AD (McKhann et al., 1984); and
the third cohort of 152 ET patients that met the Washington
Heights-Inwood Genetic Study of ET (WHIGET) diagnosis cri-
teria (Louis et al., 1997). All patients were recruited from the
outpatient neurology clinics of the Xiangya Hospital, Central
South University. In total, 314 healthy Chinese individuals were
recruited from the Xiangya Wellness Center as a control group.
Informed consents for participation in the study were obtained
from all subjects, including patients and controls. This study
received prior approval by the institutional review board and
the ethics committee of the Xiangya Hospital, Central South
University.
METHODS
Genomic DNA was isolated from peripheral blood leukocytes
using a QIAGEN kit. We screened the presence of the GGGGCC
hexanucleotide expansion of C9orf72 using a 2-step polymerase
chain reaction protocol. In the first step, we used a previ-
ously reported repeat-primed polymerase chain reaction assay to
detect the size of the larger expanded alleles (Dejesus-Hernandez
et al., 2011). Briefly, DNA samples (50 ng/µl) were amplified
using three primers (MRX-F: 5′FAM-ACAGTACTCGCTGAG
GGTGAAC; MRX-R1: 5′CAGGAAACAGCTATGACCGGGCCC
GCCCCGACCACGCCCCGGCCCCGGCCCCGG; MRX-M13R:
5′CAAGGAAACAGCTATGACC), and the primers ratio (0.6µl
of 10µM of MRX-F; 0.6µl of 10µM of MRX-M13R; 0.1µl
of 10µM of MRX-R1) were modified to improve the efficiency
of the PCR. Other components of the PCR reaction included
the following: 1_µl of 50_ng/µl of DNA samples, 2_µl of
5× Q-solution (QIAGEN Valencia, CA, USA), 0.7µl of 100%
DMSO (Sigma-Aldrich), 0.36µl of 7-deaza-dGTP (New England
Biolabs, Ipswich, MA, USA), 0.2µl of Roche FastStart Taq DNA
polymerase, 0.2µl of 10µMdNTP and 1µl of 10× Buffer (Roche
Applied Science, Indianapolis, IN, USA), and 3.24µl MQ. The
total process was performed using a touchdown thermocycling
program. The reaction conditions consisted of 95◦C for 5min,
15 cycles of 95◦C for 1min, 70◦C for 1min, with a decrement
of 1◦C per cycle, 72◦C for 3min, followed by 25 cycles of 95◦C
for 1min, 56◦C for 1min, 72◦C for 3min, 72◦C for 60min, the
final temperature was then sustained at 15◦C. In the second step,
we performed a classical FAM-fluorescent labeled PCR assay to
detect the accurate genotype of the non-pathogenic mutation car-
riers. The fragment length analysis was performed on an ABI
3730×l DNA analyzer and was visualized by the GeneMapper
software version 3.2 (Applied Biosystems).
STATISTICAL ANALYSIS
A cut-off value of 30 repeats was used to define the pathogenic
threshold (Renton et al., 2011). One DNA sample of an ALS
patient who was recruited from the Xiangya Hospital was sub-
jected to a repeat-primed polymerase chain reaction, and >30
repeat expansions were detected (unpublished paper), which
could verify the reliability and trustworthiness of our experiment.
Descriptive statistics were expressed as the mean ± the stan-
dard deviation; differences in the distributions of repeat number
between the patients and controls were tested using a 2-tailed
Mann-Whitney U-test or Kruskal–Wallis H-test, and significance
was set at p = 0.05. Considering that the role of ≥7 units in
non-pathogenic carriers was strongly correlated with C9orf72
expression (Van Der Zee et al., 2013), all subjects were classified
into three genotypes, including S/S, S/I, and I/I (S: short allele<7
units; I: intermediate allele≥7_units) according to an individual’s
two repeat alleles. The associations between the number of repeat
and disease risk were determined in logistic regression models
that were adjusted for the age at onset and gender. Analyses of
the associations between the number of repeats and the age at
onset were calculated using linear regression models that were
adjusted for gender. To adjust p-values for multiple testing, we
performed Bonferroni adjustment in logistic regression and lin-
ear regression. The statistical analysis was performed using the
SPSS program (version 18.0).
RESULTS
Table 1 presents the demographic information for our study.
A total of 1342 patients and 314 healthy controls were successfully
subjected to repeat-primed polymerase chain reactions and geno-
typing. However, no pathological repeat expansion ofC9orf72was
detected in either patients or controls. The wide range of repeat
expansions in patients was 2–27 units, and the most frequent
repeats in all subjects was 2 units, followed by 6, 7, and 8; however,
three PD patients harbored marginally larger alleles at 22, 23, and
27 units. In addition, the distributions of repeat numbers in the
individuals’ larger allele indicated a significant difference in PD
(p = 0.01), late onset PD (>50 years) (p = 0.01), and male PD
(p = 0.03) when compared with controls. However, no statistical
Table 1 | Demographic information and average number of repeats
among cases and controls.
Variable PD AD ET Controls
Cases, n 911 279 152 314
Gender, Male (%) 533 (58.5) 167 (59.9) 89 (58.6) 158 (50.3)
Age 59.0 ± 11.6 72.4 ± 12.0 44.7 ± 15.8 57.1 ± 13.7
Age at onset 55.1 ± 11.7 70.1 ± 10.0 35.4 ± 14.9 –
Repeat number 5.9 ± 3.2 5.4 ± 2.9 5.4 ± 3.1 5.3 ± 2.9
The sample mean ± SD is given for age, age at onset, and repeat number.
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significance was found in AD (p = 0.67), ET (p = 0.13) or their
subtypes when compared with control individuals (Figure 1 and
Table 2).
Given the significant distinction of repeat length in PD and
control individuals, 202 PD patients who completed a bat-
tery of neuropsychological tests that were recommended by the
Movement Disorder Society (MDS) Task Force, were further
divided into 70 PD dementia (PD-D), 58 PD mild cognitive
impairment (PD-MCI), and 74 PD with no cognitive impairment
(PD-NC) according to the MDS Task Force diagnosis crite-
ria(Dubois et al., 2007). However, no significant difference in the
distribution of repeats was found among the three subgroups and
control individuals (p = 0.98) using Kruskal–Wallis H-test.
In addition, we employed two analytical approaches for associ-
ation testing, the larger repeat allele as a continuous variable and
three genotyping categorical variables based on the individual’s
short or intermediate alleles. We did not identify any significant
evidence of associations between the number of repeat and either
the AD or ET risk or the age at onset in patients with PD or ET.
Interestingly, we observed a statistically significant result between
the I/I genotype and the age at onset (p = 0.007; Regression
coefficient 5.50 [0.27, 10.74]) after Bonferroni adjustment for
multiple testing, but not in the continuous variable (p = 0.93)
(Table 3). Finally, the only significant evidence of association
was found between the repeat length and PD risk after using
Bonferroni adjustment when considering repeats as a continuous
variable (p = 0.001, OR 1.06 [1.01, 1.10]), or when considering
three genotypes as a categorical variable (p = 0.0081; S/I: OR 1.37
[1.05, 1.79]; I/I: OR 2.03 [1.17, 3.54]) (Table 4).
DISCUSSION
Recently, GGGGCC repeat expansions in the C9orf72 gene were
identified as major contributing factors for ALS and FTD.
However, the preliminary evidence suggested that the C9orf72
mutation rates in patients with clinically diagnosed ALS in China,
Japan, Korea, and Taiwan were much lower than that observed
in Caucasian populations (Ogaki et al., 2012; Tsai et al., 2012;
Zou et al., 2012; Jang et al., 2013), which implied that the
number of repeats varied greatly due to different nationalities
and ethnicities. Given the clinical heterogeneity with the repeat
expansions, we hypothesized that the length of repeats may also
account for other neurodegenerative disorders. To investigate
the hexanucleotide repeat expansions of C9orf72 on different
genetic backgrounds, we screened for C9orf72 in a large group
AD, PD, and ET patients with Chinese Han origin. To the best
of our knowledge, this study is the first reported investiga-
tion of C9orf72 repeat expansions in three cohorts of patients
in Asia.
In this study, no pathogenic expansion was observed in either
patients or controls, which supported recent data from other
independent cohorts. Across these studies, no abnormal repeats
were found in 781 patients with PD and 568 patients with AD
(Majounie et al., 2012a; Rollinson et al., 2012). The relation
between AD, PD, and C9orf72 has been controversial. Several
studies have reported that pathogenic repeats were found in 0.7%
patients with PD and in less than 1% of clinically diagnosed
AD patients (Majounie et al., 2012b; Xi et al., 2012). However,
Majounie et al. speculated that the positive results in AD patients
might be an incidental rather than a causative finding due to
FIGURE 1 | Distributions of repeat number in C9orf72 in
Alzheimer’s disease, Parkinson disease, essential tremor, and
control individuals. There was no significant difference in the
distributions of repeat length between AD (p = 0.67), ET (p = 0.13)
cases and controls, respectively. However, an evidence of significant
distribution was identified between PD cases and controls (p = 0.01);
17+ in PD patients including five PD cases at 18, 19, 22, 23, 27
repeats.
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Table 2 | Analysis of the distributions of repeat expansion in cases with different classification.
EOAD vs. Control LOAD vs. Control
N Mean ± SD P N Mean ± SD P
Cases 71 5.5 ± 2.8 0.86 208 5.4 ± 3.0 0.77
Controls 230 5.3 ± 2.9 84 5.3 ± 2.9
Male in AD vs. Control Female in AD vs. Control
Cases 106 5.7 ± 2.9 0.36 173 5.3 ± 2.9 0.77
Controls 158 5.2 ± 2.9 156 5.4 ± 2.8
EOPD vs. Control LOPD vs. Control
Cases 286 5.6 ± 2.0 0.19 603 6.0 ± 3.2 0.01
Controls 85 5.2 ± 2.7 229 5.4 ± 2.9
Male in PD vs. Control Female in PD vs. Control
Cases 533 5.9 ± 3.0 0.03 378 5.9 ± 3.3 0.07
Controls 158 5.3 ± 2.9 156 5.4 ± 2.8
Male in ET vs. Control Female in ET vs. Control
Cases 89 5.5 ± 3.2 0.61 63 5.2 ± 2.9 0.57
Controls 158 5.2 ± 2.9 156 5.4 ± 2.8
EOAD, early onset AD (≤65 years); LOAD, late onset AD (>65 years); EOPD, early onset PD (≤50 years); LOPD, late onset PD (>50 years).
Table 3 | Association of allele length with age at onset in patients with PD, AD, and ET.
Association of allele length with age at onset
PD (n = 911) AD (n = 279) ET (n = 152)
Regression coefficient (95% CI) P Regression coefficient (95% CI) P Regression coefficient (95% CI) P
Genotype 0.43 0.007 0.85
S/S 0.00 (reference) 0.00 (reference) 0.00 (reference)
S/I 0.02 (−1.60, 1.63) 1.04 (−1.90, 3.98) −0.15 (−3.85, 3.55)
I/I 1.37 (−1.41, 4.16) 5.50 (0.27, 10.74) −0.32 (−7.57, 6.93)
Repeats on larger allele continuous
0.20 (−0.48, −0.44) 0.12 0.02 (−0.46, 0.50) 0.93 −0.47 (−1.20, 0.25) 0.20
CI, confidence interval; S, short allele (<7 units); I, intermediate allele (≥7 units).
Regression coefficient and corresponding p results from linear regression models adjusted for gender. After Bonferroni adjustment for multiple testing, p ≤ 0.025
were considered statistically significant (2 tests).
Table 4 | Association of allele length with risk of PD, AD, and ET diseases.
Association of allele length with risk of disease in comparison with controls (n = 314)
PD (n = 911) AD (n = 279) ET (n = 152)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Genotype 0.0081 0.54 0.64
S/S 1.00 (reference) 1.00 (reference) 1.00 (reference)
S/I 1.37 (1.05, 1.79) 0.83 (0.55, 1.26) 0.88 (0.57, 1.37)
I/I 2.03 (1.17, 3.54) 0.91 (0.40, 2.06) 1.30 (0.56, 3.04)
Repeats on larger allele continuous
1.06 (1.01, 1.10) 0.001 0.99 (0.93, 1.05) 0.69 0.96 (0.89, 1.03) 0.27
OR, odds ratio; CI, confidence interval; S, short allele (<7 units); I, intermediate allele (≥7 units).
Odds ratios and corresponding p-value results from logistic regression models adjusted for age at onset and gender. After Bonferroni adjustment for multiple testing,
p ≤ 0.0083 were considered statistically significant (6 tests).
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amnesic FTD being misdiagnosed as probable AD (Majounie
et al., 2012b).
There are three possible explanations for our negative results.
The first possibility is that the hexanucleotide repeat expansions
could not cause PD, AD, or ET, and is only specific to ALS/FTD.
Although the pathogenic gene mutations were detected in several
probable cases of PD or AD, the exact diagnoses of these diseases
should be confirmed due to clinical heterogeneity. Another expla-
nation for the result is that the cut-off value of repeat >30 units
that is suitable for ALS/FTD is most likely not suitable for AD, PD,
or ET patients, andmore samples should be included to set a solid
cut-off value. Finally, Mok et al. found that the ALS/FTD patients
with C9orf72 pathogenic repeats share a similar risk haplotype
with Finland, Ireland, Italy, UK, and USA populations. Moreover,
an investigation from Japan suggests that the pathogenic expan-
sion is closely tied to the risk haplotype, and the low frequency
of the risk haplotype might explain the low frequency of repeat
expansions (Konno et al., 2012).
Although no pathogenic expansion was observed in this
study, we identified a significant association between the num-
ber of intermediate repeats and PD risk, which indicates that
the more intermediate repeats, the greater risk of susceptibil-
ity to PD. As we know, this study is the first to raise this
notion. This notion suggests that the intermediate alleles act
as a contributor to PD risk. Although our research to eluci-
date the disease mechanism of this intermediate repeat remains
in its infancy, one previous study has indicated that intermedi-
ate repeats could decrease the transcriptional activity of C9orf72
(Van Der Zee et al., 2013). Therefore, how the intermediate
alleles act as predisposing alleles and what is the pathogenic path-
way of intermediate alleles in PD patients should be addressed
in further studies. In addition, this study reported that there
was no significant difference in repeat expansions among PDD,
PD-MCI, PD-NC patients, and control individuals, which indi-
cated that the number of repeats in C9orf72 might not account
for the occurrence and severity of cognitive syndromes in PD
patients.
Recently, Kohli et al. (2013) found nine AD patients that car-
ried the C9orf72 mutation with an average disease onset of 77.8
years (all older than 60 years), and speculated that the pathogenic
repeat expansions were most likely associated with late onset AD
(>65 years). Similarly, in this study, we observed a positive cor-
relation between the I/I genotype and the age at onset, which
indicated that AD patients who carried I/I genotypes were suscep-
tible to a higher age at onset. At present, APOE4 is the only major
genetic risk factor for the development of late onset AD (Hauser
and Ryan, 2013), if the relation above exists, then future research
will focus on exploring whether there is an interaction mecha-
nism between these two genes in patients with late onset AD.
Finally, there was only a cohort of 106 ET patients that were inves-
tigated before our study, and this cohort had the identical result as
our study, with no association of normal repeat length with dis-
ease risk or with an effect on age at onset, further confirming that
GGGGCC repeats did not play a role in patients with ET.
However, there are several limitations in this work. First, an
association between the I/I genotype and the age at onset in AD
patients might be a false positive observation due to the lack
of a statistically significance correlation between the larger alle-
les (continuous variables) and the age at onset. Therefore, we
should recruit more samples to verify the relation between the
repeat expansions in C9orf72 and the age at onset in patients with
AD. Second, if the relation above was further verified, then we
should assess the relation between the C9orf72 repeats and APOE
genotypes to explore whether there is an interaction mechanism
between them. Third, this study only examined sporadic AD, PD,
and ET patients, C9orf72 may play a role in dominant familial
forms.
In conclusion, no C9orf72 pathogenic mutations in AD,
PD, and ET patients in this study are consistent with previ-
ous studies (Majounie et al., 2012b; Dejesus-Hernandez et al.,
2013). However, we identified a statistically significant association
between the intermediate repeats and PD risk, which implied that
intermediate genotypes or alleles might be a risk factor for PD in
China. Meanwhile, the lack of association between the intermedi-
ate repeats and AD risk has indicated that intermediate genotypes
or alleles might play a different role in AD and PD.
AUTHOR CONTRIBUTIONS
Lu Shen, Beisha Tang, and Kun Xia contributed to the conception
and organization of our research project; Bin Jiao, Jifeng Guo,
Xinxiang Yan, and Lin Zhou contributed to recruiting patients
and controls; Bin Jiao, Jifeng Guo, Yaqin Wang, Xiaoyan Liu,
Fufeng Zhang, and Yafang Zhou contributed to statistical anal-
ysis; Bin Jiao and Jifeng Guo equally contributed to the first draft,
and Lu Shen was responsible for the review and critique of our
manuscript.
ACKNOWLEDGMENTS
We are grateful to all subjects for their participation in our study.
This study was supported by the National Basic Research Program
(973 Program) (No. 2011CB510000 to Lu Shen) and the National
Natural Science Foundation of China (No. 81171068 to Lu Shen).
REFERENCES
Arighi, A., Fumagalli, G. G., Jacini, F.,
Fenoglio, C., Ghezzi, L., Pietroboni,
A. M., et al. (2012). Early onset
behavioral variant frontotemporal
dementia due to the C9ORF72
hexanucleotide repeat expansion:
psychiatric clinical presentations.
J. Alzheimers Dis. 31, 447–452.
Boeve, B. F., Boylan, K. B., Graff-
Radford, N. R., Dejesus-Hernandez,
M., Knopman, D. S., Pedraza, O.,
et al. (2012). Characterization of
frontotemporal dementia and/or
amyotrophic lateral sclerosis asso-
ciated with the GGGGCC repeat
expansion in C9ORF72. Brain 135,
765–783. doi: 10.1093/brain/aws004
Cacace, R., Van Cauwenberghe, C.,
Bettens, K., Gijselinck, I., Van
Der Zee, J., Engelborghs, S.,
et al. (2013). C9orf72 G(4)C(2)
repeat expansions in Alzheimer’s
disease and mild cognitive impair-
ment. Neurobiol. Aging 34,
1712.e1–1712.e7. doi: 10.1016/
j.neurobiolaging.2012.12.019
Dejesus-Hernandez, M., Mackenzie,
I. R., Boeve, B. F., Boxer, A. L.,
Baker, M., Rutherford, N. J., et al.
(2011). Expanded GGGGCC
hexanucleotide repeat in noncod-
ing region of C9ORF72 causes
chromosome 9p-linked FTD and
ALS. Neuron 72, 245–256. doi:
10.1016/j.neuron.2011.09.011
Dejesus-Hernandez, M., Rayaprolu, S.,
Soto-Ortolaza, A. I., Rutherford,
N. J., Heckman, M. G., Traynor,
S., et al. (2013). Analysis of the
C9orf72 repeat in Parkinson’s
disease, essential tremor
and restless legs syndrome.
Parkinsonism Relat. Disord. 19,
Frontiers in Cellular Neuroscience www.frontiersin.org September 2013 | Volume 7 | Article 164 | 5
Jiao et al. C9orf72 repeats in neurodegenerative diseases
198–201. doi: 10.1016/j.parkreldis.
2012.09.013
Dubois, B., Burn, D., Goetz, C.,
Aarsland, D., Brown, R. G., Broe,
G. A., et al. (2007). Diagnostic
procedures for Parkinson’s dis-
ease dementia: recommendations
from the movement disorder soci-
ety task force. Mov. Disord. 22,
2314–2324. doi: 10.1002/mds.21844
Floris, G., Borghero, G., Cannas, A., Di
Stefano, F., Costantino, E., Murru,
M. R., et al. (2012). Frontotemporal
dementia with psychosis, parkin-
sonism, visuo-spatial dysfunction,
upper motor neuron involve-
ment associated to expansion of
C9ORF72: a peculiar phenotype?
J. Neurol. 259, 1749–1751. doi:
10.1007/s00415-012-6444-3
Gijselinck, I., Van Langenhove, T.,
Van Der Zee, J., Sleegers, K.,
Philtjens, S., Kleinberger, G., et al.
(2012). A C9orf72 promoter repeat
expansion in a Flanders-Belgian
cohort with disorders of the
frontotemporal lobar degeneration-
amyotrophic lateral sclerosis
spectrum: a gene identification
study. Lancet Neurol. 11, 54–65. doi:
10.1016/S1474-4422(11)70261-7
Hauser, P. S., and Ryan, R. O. (2013).
Impact of apolipoprotein E on
Alzheimer’s disease. Curr. Alzheimer
Res. [Epub ahead of print].
Hsiung, G. Y., Dejesus-Hernandez,
M., Feldman, H. H., Sengdy,
P., Bouchard-Kerr, P., Dwosh,
E., et al. (2012). Clinical and
pathological features of familial
frontotemporal dementia caused by
C9ORF72 mutation on chromo-
some 9p. Brain 135, 709–722. doi:
10.1093/brain/awr354
Hudson, A. J. (1981). Amyotrophic
lateral sclerosis and its association
with dementia, parkinsonism
and other neurological dis-
orders: a review. Brain 104,
217–247. doi: 10.1093/brain/
104.2.217
Hughes, A. J., Daniel, S. E., Kilford,
L., and Lees, A. J. (1992). Accuracy
of clinical diagnosis of idio-
pathic Parkinson’s disease: a
clinico-pathological study of
100 cases. J. Neurol. Neurosurg.
Psychiatr. 55, 181–184. doi:
10.1136/jnnp.55.3.181
Jang, J. H., Kwon, M. J., Choi, W.
J., Oh, K. W., Koh, S. H., Ki,
C. S., et al. (2013). Analysis of
the C9orf72 hexanucleotide repeat
expansion in Korean patients with
familial and sporadic amyotrophic
lateral sclerosis. Neurobiol. Aging
34, 1311.e7–1319.e9. doi: 10.1016/
j.neurobiolaging.2012.09.004
Kohli, M. A., John-Williams,
K., Rajbhandary, R., Naj, A.,
Whitehead, P., Hamilton, K.,
et al. (2013). Repeat expan-
sions in the C9ORF72 gene
contribute to Alzheimer’s disease
in Caucasians. Neurobiol. Aging 34,
1519.e5–1519.e12. doi: 10.1016/
j.neurobiolaging.2012.10.003
Konno, T., Shiga, A., Tsujino, A.,
Sugai, A., Kato, T., Kanai, K.,
et al. (2012). Japanese amy-
otrophic lateral sclerosis patients
with GGGGCC hexanucleotide
repeat expansion in C9ORF72.
J. Neurol. Neurosurg. Psychiatr. 84,
398–401. doi: 10.1136/jnnp-2012-
302272
Lesage, S., Le Ber, I., Condroyer, C.,
Broussolle, E., Gabelle, A., Thobois,
S., et al. (2013). C9orf72 repeat
expansions are a rare genetic
cause of parkinsonism. Brain 136,
385–391. doi: 10.1093/brain/aws357
Louis, E. D., Ottman, R., Ford, B.,
Pullman, S., Martinez, M., Fahn,
S., et al. (1997). The washington
heights-inwood genetic study of
essential tremor: methodologic
issues in essential-tremor research.
Neuroepidemiology 16, 124–133.
doi: 10.1159/000109681
Majounie, E., Abramzon, Y., Renton,
A. E., Keller, M. F., Traynor, B. J.,
and Singleton, A. B. (2012a). Large
C9orf72 repeat expansions are not
a common cause of Parkinson’s
disease. Neurobiol. Aging 33,
2527.e1–2527.e2. doi: 10.1016/
j.neurobiolaging.2012.05.007
Majounie, E., Abramzon, Y., Renton,
A. E., Perry, R., Bassett, S. S.,
Pletnikova, O., et al. (2012b).
Repeat expansion in C9ORF72
in Alzheimer’s disease. N. Engl.
J. Med. 366, 283–284. doi:
10.1056/NEJMc1113592
McKhann, G., Drachman, D., Folstein,
M., Katzman, R., Price, D., and
Stadlan, E. M. (1984). Clinical
diagnosis of Alzheimer’s disease:
report of the NINCDS-ADRDA
Work Group under the auspices
of Department of Health and
Human Services Task Force on
Alzheimer’s Disease. Neurology
34, 939–944. doi: 10.1212/
WNL.34.7.939
Nakashima-Yasuda, H., Uryu,
K., Robinson, J., Xie, S. X.,
Hurtig, H., Duda, J. E., et al.
(2007). Co-morbidity of TDP-
43 proteinopathy in Lewy
body related diseases. Acta
Neuropathol. 114, 221–229. doi:
10.1007/s00401-007-0261-2
O’Dowd, S., Curtin, D., Waite,
A. J., Roberts, K., Pender, N.,
Reid, V., et al. (2012). C9ORF72
expansion in amyotrophic lateral
sclerosis/frontotemporal demen-
tia also causes parkinsonism.
Mov. Disord. 27, 1072–1074. doi:
10.1002/mds.25022
Ogaki, K., Li, Y., Atsuta, N., Tomiyama,
H., Funayama, M., Watanabe, H.,
et al. (2012). Analysis of C9orf72
repeat expansion in 563 Japanese
patients with amyotrophic lateral
sclerosis. Neurobiol. Aging 33,
2527.e11–2526.e6. doi: 10.1016/
j.neurobiolaging.2012.05.011
Piguet, O., Hornberger, M., Mioshi,
E., and Hodges, J. R. (2011).
Behavioural-variant frontotem-
poral dementia: diagnosis,
clinical staging, and management.
Lancet Neurol. 10, 162–172. doi:
10.1016/S1474-4422(10)70299-4
Renton, A. E., Majounie, E., Waite,
A., Simon-Sanchez, J., Rollinson,
S., Gibbs, J. R., et al. (2011).
A hexanucleotide repeat expan-
sion in C9ORF72 is the cause
of chromosome 9p21-linked ALS-
FTD. Neuron 72, 257–268. doi:
10.1016/j.neuron.2011.09.010
Rollinson, S., Halliwell, N., Young,
K., Callister, J. B., Toulson, G.,
Gibbons, L., et al. (2012). Analysis
of the hexanucleotide repeat
in C9ORF72 in Alzheimer’s
disease. Neurobiol. Aging 33,
1846.e5–1846.e6. doi: 10.1016/
j.neurobiolaging.2012.01.109
Sha, S. J., and Boxer, A. (2012).
Treatment implications of
C9ORF72. Alzheimers Res. Ther. 4,
46. doi: 10.1186/alzrt149
Takada, L. T., Pimentel, M. L., Dejesus-
Hernandez, M., Fong, J. C.,
Yokoyama, J. S., Karydas, A.,
et al. (2012). Frontotemporal
dementia in a Brazilian kin-
dred with the c9orf72 mutation.
Arch. Neurol. 69, 1149–1153. doi:
10.1001/archneurol.2012.650
Tsai, C. P., Soong, B. W., Tu, P. H.,
Lin, K. P., Fuh, J. L., Tsai, P. C.,
et al. (2012). A hexanucleotide
repeat expansion in C9ORF72
causes familial and sporadic ALS
in Taiwan. Neurobiol. Aging 33,
2232.e11–2232.e18. doi: 10.1016/
j.neurobiolaging.2012.05.002
Van Der Zee, J., Gijselinck, I., Dillen,
L., Van Langenhove, T., Theuns, J.,
Engelborghs, S., et al. (2013). A
pan-european study of the C9orf72
repeat associated with FTLD: geo-
graphic prevalence, genomic insta-
bility, and intermediate repeats.
Hum. Mutat. 34, 363–373. doi:
10.1002/humu.22244
Xi, Z., Zinman, L., Grinberg, Y.,
Moreno, D., Sato, C., Bilbao, J.
M., et al. (2012). Investigation of
C9orf72 in 4 neurodegenerative dis-
orders. Arch. Neurol. 69, 1583–1590.
doi: 10.1001/archneurol.2012.2016
Zou, Z. Y., Li, X. G., Liu, M. S.,
and Cui, L. Y. (2012). Screening
for C9orf72 repeat expansions
in Chinese amyotrophic lateral
sclerosis patients. Neurobiol. Aging.
34, 1710.e5–1710.e6. doi: 10.1016/
j.neurobiolaging.2012.03.014
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 09 July 2013; paper pending
published: 08 August 2013; accepted: 04
September 2013; published online: 24
September 2013.
Citation: Jiao B, Guo J, Wang Y, Yan X,
Zhou L, Liu X, Zhang F, Zhou Y, Xia
K, Tang B and Shen L (2013) C9orf72
mutation is rare in Alzheimer’s disease,
Parkinson’s disease, and essential tremor
in China. Front. Cell. Neurosci. 7:164.
doi: 10.3389/fncel.2013.00164
This article was submitted to the journal
Frontiers in Cellular Neuroscience.
Copyright © 2013 Jiao, Guo, Wang,
Yan, Zhou, Liu, Zhang, Zhou, Xia, Tang
and Shen. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or repro-
duction in other forums is permitted,
provided the original author(s) or licen-
sor are credited and that the original
publication in this journal is cited, in
accordance with accepted academic prac-
tice. No use, distribution or reproduction
is permitted which does not comply with
these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org September 2013 | Volume 7 | Article 164 | 6
